Covid-19: From structure to therapeutic targeting in studying approved drugs and local DNA vaccination

Clin Exp Pharmacol Physiol. 2020 Nov;47(11):1771-1773. doi: 10.1111/1440-1681.13409.

Authors

Zhiguo Wang¹, Xiaojing Hong¹, Hongyan Wang¹, Jun Liu¹, Jun-Ping Liu^{1

2

3

4}

Affiliations

¹ Institute of Ageing Research, Hangzhou Normal University, School of Medicine, Hangzhou, China.
² Department of Immunology, Central Clinical School, Faculty of Medicine, Monash University, Prahran, Vic., Australia.
³ Hudson Institute of Medical Research, Clayton, Vic., Australia.
⁴ Department of Molecular and Translational Science, Faculty of Medicine, Monash University, Clayton, Vic., Australia.

No abstract available

Publication types

Editorial
Introductory Journal Article
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use*
COVID-19
COVID-19 Drug Treatment
COVID-19 Vaccines
Coronavirus Infections / drug therapy*
Coronavirus Infections / prevention & control
Humans
Pandemics / prevention & control
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / prevention & control
Vaccines, DNA / therapeutic use*
Viral Vaccines / therapeutic use*

Substances

Antiviral Agents
COVID-19 Vaccines
Vaccines, DNA
Viral Vaccines

Grants and funding